Binds to activated CDC42 but does not stimulate its GTPase activity. It associates with calmodulin. Could serve as an assembly scaffold for the organization of a multimolecular complex that would interface incoming signals to the reorganization of the actin cytoskeleton at the plasma membrane. May promote neurite outgrowth. Interacts with CDC42; the interaction is demonstrated with IQGAP1 in GTP-bound and in nucleotide-free state. Interacts with RAC1. Does not interact with RHOA. Interacts with TSG101. Interacts with PAK6. Expressed in the placenta, lung, and kidney. A lower level expression is seen in the heart, liver, skeletal muscle and pancreas. Note: This description may include information from UniProtKB.
Protein type: GAPs, Ras; Motility/polarity/chemotaxis; GAPs
Chromosomal Location of Human Ortholog: 15q26.1
Cellular Component: microtubule; neuron projection; extrinsic to internal side of plasma membrane; leading edge; cytoplasm; nucleolus; plasma membrane; actin filament; midbody; cell junction; nucleus; lateral plasma membrane
Molecular Function: calmodulin binding; protein serine/threonine kinase activator activity; protein binding; phosphatidylinositol-3,4,5-triphosphate binding; Rac GTPase binding; protein complex binding; calcium ion binding; Ras GTPase activator activity; protein kinase binding; protein phosphatase binding; GTPase activator activity; GTPase inhibitor activity
Biological Process: epidermal growth factor receptor signaling pathway; positive regulation of Ras GTPase activity; positive regulation of protein kinase activity; negative regulation of dephosphorylation; small GTPase mediated signal transduction; negative regulation of catalytic activity; energy reserve metabolic process; signal transduction; regulation of insulin secretion; positive regulation of GTPase activity; regulation of cytokine production
SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.